top of page

Publications

ASH 2021 Presentation:

Aspacytarabine (BST-236) as Monotherapy is Safe, Well-tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study

ASH 2020 Presentation:

Durable Remissions and Increased Overall Survival in AML Patients Unfit for Standard Intensive Chemotherapy Achieved with High-Dose Aspacytarabine (BST-236) Induction and Consolidation

ASH 2021.png
ASH.png

ASH 2019 Oral Presentation:

Aspacytarabine (BST-236) is Safe and Efficacious as a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy

Blood Adv. 2019 Nov 26; 3(22): 3740–3749:

BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study

ASH 2018 Abstract: BST-236 Mechanism of Action

BST-236, a Novel Cytarabine Prodrug, Is Safer and As Effective As Cytarabine in In Vivo Leukemia Models

ASH.png
logo-bloodadv.png
ASH 2018 Poster BST-236 MoA small.png
KOLs speak of BST-236:
Aspacytarabine (BST-236) as a potential new frontline therapy option for patients with AML that are unfit for intensive chemotherapy
An AML Global Portal interview of Dr. Selina Luger during ASH 2019
AML Global interview ASH 2019.png
bottom of page